Serpin A-3 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Alpha-1-antichymotrypsin (SERPINA3, UniProt P01011) produced in HEK293 cells. Suited for protease inhibition assays, inhibitor screening, and antibody validation paired with RP-SerpinA3.
Expression system
HEK293
Cat. #
REC-SerpinA3

In stock

SKU
REC-SerpinA3
$498.00

Target Overview

Serpin A-3, encoded by SERPINA3, is a secreted serine protease inhibitor belonging to the serpin superfamily. The full-length human protein spans 423 amino acids (UniProt P01011). This recombinant form is expressed in HEK293 mammalian cells, providing post-translational modifications — including glycosylation — that are characteristic of the natively secreted protein and relevant to functional and binding studies. Serpin A-3 inhibits neutrophil cathepsin G and mast cell chymase, both chymotrypsin-like serine proteases. Because cathepsin G and chymase can each convert angiotensin-1 to angiotensin-2, Serpin A-3 sits at an intersection of protease biology and peptide hormone processing that is actively studied in cardiovascular and inflammatory contexts. The physiological regulation of this inhibitory activity remains an open research question. Researchers use this recombinant protein in several in-vitro contexts: substrate-competition and inhibition-kinetics assays against cathepsin G or chymase, second-order rate-constant (k_ass) determinations, and small-molecule or peptide inhibitor counter-screening where a cognate serpin serves as a selectivity benchmark. Because Serpin A-3 is a secreted acute-phase protein detected in plasma and extracellular vesicle proteomes, the HEK293-expressed recombinant is also used as a calibration standard in quantitative proteomics workflows and as a positive-control antigen in Western blot and ELISA development. Researchers requiring an antibody reagent for immunodetection can pair this recombinant directly with the Triple Point Biologics matched antibody (SKU: RP-SerpinA3), which has been validated for Western blot against human SERPINA3. Together, the pair provides a matched antigen–antibody system for antibody titration, lot-to-lot consistency checks, and assay development.

Background

Alpha-1-antichymotrypsin (SERPINA3) is a glycoprotein secreted primarily by hepatocytes and, at lower levels, by a range of other cell types including astrocytes, monocytes, and certain epithelial cells. It is classified as an acute-phase reactant: plasma concentrations rise substantially during systemic inflammation, infection, and tissue injury, placing it alongside alpha-1-antitrypsin and C-reactive protein as an established marker of acute-phase response. At the mechanistic level, Serpin A-3 operates through the canonical serpin suicide-inhibition mechanism. It presents a reactive centre loop (RCL) that acts as bait for its target protease; upon cleavage, a covalent acyl-enzyme intermediate forms and the inhibitor undergoes a large conformational change that traps and irreversibly inactivates the protease. The primary documented targets are neutrophil cathepsin G and mast cell chymase — chymotrypsin-like enzymes prominent in innate immune signalling and mast-cell-dependent tissue remodelling. SERPINA3 has been studied as a research target across a broad range of disease-associated contexts. In neurodegeneration, SERPINA3 protein has been detected in amyloid plaques and reactive astrocytes in Alzheimer's disease brain tissue, and a 2026 study identified it among common biomarkers shared between Alzheimer's disease and postoperative delirium (Fang Y et al., Medicine (Baltimore), 2026; PMID 42216384), supporting its use as a biomarker analyte in CNS-focused research panels. In oncology research, SERPINA3 expression has been characterised as associated with poor prognosis and T-cell dysfunction signatures in non-small cell lung cancer, suggesting a role in tumour immune microenvironment studies. Separately, it has been identified as an endoplasmic reticulum stress-related gene of interest in neuroblastoma prognostic modelling. In infectious disease and sepsis research, SERPINA3 has been detected in extracellular vesicle proteomes from Staphylococcus aureus-treated blood, placing it within the coordinated acute-phase and complement responses observed in bacterial sepsis models. An exploratory case-control study has also measured plasma SERPINA3 levels in adolescent major depressive disorder, reflecting interest in the protein as a peripheral inflammatory marker in psychiatric research. Collectively, these published contexts — neurodegeneration, oncology, sepsis, and psychiatry — illustrate the breadth of research settings in which a well-characterised, mammalian-expressed recombinant Serpin A-3 serves as an antigen standard, an inhibitor-assay component, or a quantitative reference material. Triple Point Biologics has produced proteinase/inhibitor reagents since 1994; this recombinant reflects that continuous focus on this protein family.

Applications

  • Cathepsin G inhibition kinetics assay (second-order association rate constant determination)
  • Mast cell chymase inhibitory activity assay using fluorogenic substrate competition
  • Small-molecule inhibitor counter-screening to assess selectivity against a cognate serpin
  • Quantitative ELISA calibration standard for plasma SERPINA3 measurement
  • Antibody validation positive control for Western blot paired with RP-SerpinA3
  • IHC antigen standard for titration of anti-SERPINA3 antibody (RP-SerpinA3)
  • Extracellular vesicle proteomic spike-in reference for mass spectrometry quantitation
  • Acute-phase protein panel benchmark in in-vitro inflammation models

References

  1. Chiang DM et al. Extracellular vesicle proteomics in staphylococcus aureus-treated blood and sepsis reveals coordinated complement, acute phase, neutrophil, and exocytosis responses. Sci Rep. 2026. doi:10.1038/s41598-026-54598-7. PMID: 42225697.
  2. Fang Y et al. Common biomarkers of Alzheimer disease and postoperative delirium. Medicine (Baltimore). 2026. doi:10.1097/MD.0000000000048921. PMID: 42216384.
  3. Lu W et al. Identification and analysis of endoplasmic reticulum stress-related genes in neuroblastoma and construction of a prognostic gene signature. Transl Cancer Res. 2026. doi:10.21037/tcr-2025-1-2623. PMID: 42180899.
  4. Xue Y et al. Plasma SERPINA3 and its clinical correlates in adolescent major depressive disorder: an exploratory case-control study. BMC Psychiatry. 2026. doi:10.1186/s12888-026-08197-5. PMID: 42163223.
  5. Kim J et al. SERPINA3 as a Secreted-Protein Biomarker Associated with Poor Prognosis and T-cell Dysfunction in Non-Small Cell Lung Cancer. Tuberc Respir Dis (Seoul). 2026. doi:10.4046/trd.2026.0014. PMID: 42145033.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What is the expected molecular weight of recombinant Serpin A-3 on SDS-PAGE and Western blot?

The full-length human Serpin A-3 polypeptide has a calculated molecular weight of ~47 kDa based on its 423-amino-acid sequence (UniProt P01011). Because this recombinant is expressed in HEK293 cells, N-linked glycosylation adds approximately 10–20 kDa, so the predominant band typically resolves at 55–68 kDa on reducing SDS-PAGE. Run alongside a broad-range ladder and do not be alarmed by smearing near the upper edge of that range — it reflects heterogeneous glycosylation, not degradation. Under denaturing conditions, a single diffuse band in that window is the expected result.

Does recombinant Serpin A-3 retain the native signal peptide and is it full-length or processed?

The secreted, mature form of human Serpin A-3 begins at residue 25 following cleavage of the 24-residue signal peptide. This recombinant is produced as the mature secreted form (residues 25–423), reflecting the species found in plasma and tissue fluid. No additional pro-peptide processing is required for inhibitory activity — the reactive center loop (RCL) is intact and accessible. The HEK293 expression system ensures the correct disulfide environment and glycosylation pattern, both of which influence RCL conformation and target-protease engagement.

What proteases does recombinant Serpin A-3 inhibit and what enzymatic substrates can I use to measure inhibition?

Serpin A-3 is a canonical inhibitor of neutrophil cathepsin G and mast cell chymase, both chymotrypsin-like serine proteases that cleave after bulky hydrophobic residues. For inhibition-kinetics assays, fluorogenic substrates such as Suc-AAPF-AMC (cathepsin G) or Suc-LLVY-AMC (chymase) at 100–200 µM in 50 mM Tris-HCl pH 7.5, 150 mM NaCl work well. Pre-incubate Serpin A-3 with the target protease for 10–15 minutes at 37°C before substrate addition to allow stoichiometric complex formation. Serpin-protease inhibition is irreversible; IC50 measurements must account for the time-dependent nature of this mechanism.

What starting concentration of recombinant Serpin A-3 should I use for cathepsin G inhibition assays?

For substrate-competition and inhibition-kinetics experiments, we recommend titrating Serpin A-3 across a 10–500 nM range against a fixed cathepsin G concentration of 10–50 nM. Because serpins act as suicide substrates and form a covalent acyl-enzyme intermediate, the stoichiometry of inhibition (SI) must be determined empirically — typically SI = 1–3 for Serpin A-3 / cathepsin G under physiological ionic conditions. Use the supplied storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) as the diluent, and confirm protein concentration by A280 or BCA before each experiment.

Can I use recombinant Serpin A-3 as a positive control for Western blot with the matched TPB antibody RP-SerpinA3?

Yes — this is one of the primary intended uses. REC-SerpinA3 and RP-SerpinA3 are produced and validated in the same lab, so compatibility is confirmed rather than assumed. Load 20–50 ng of REC-SerpinA3 per lane on a 10–12% SDS-PAGE gel; the antibody detects the glycosylated band at 55–68 kDa under reducing conditions. RP-SerpinA3 is a rabbit polyclonal validated for Western blot. Using the recombinant as a positive control alongside your cell lysate or plasma sample removes ambiguity about whether a negative result reflects absent target or antibody failure.

How much recombinant Serpin A-3 should I load for a Western blot positive control lane?

20–50 ng per lane is sufficient for a clean positive control band using RP-SerpinA3 at a 1:1,000–1:2,000 dilution with standard ECL detection. At 20 ng you will see a clear band without overwhelming neighboring sample lanes; scale up to 50 ng if your ECL exposure windows are short or if you are titrating antibody concentration. Prepare a working dilution of REC-SerpinA3 in 1× Laemmli sample buffer and boil for 5 minutes. The resolved band at 55–68 kDa confirms both antibody functionality and correct molecular weight expectation for endogenous Serpin A-3 in your experimental samples.

What buffer conditions are optimal for Serpin A-3 activity assays and does glycerol interfere?

Serpin A-3 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For most activity assays, diluting 10-fold or more into assay buffer reduces glycerol to ≤1%, which does not meaningfully affect cathepsin G or chymase kinetics. Avoid PBS without supplemental NaCl — ionic strength below 100 mM can destabilize the RCL conformation. If your assay requires detergent (e.g., 0.01% Tween-20 to reduce surface adhesion), confirm that total detergent remains below the CMC. pH should be held at 7.0–7.6; Serpin A-3 inhibitory activity drops measurably below pH 6.5.

How should I store and handle recombinant Serpin A-3 to preserve activity over time?

Store at -20°C in the single-use aliquots as supplied. Repeated freeze-thaw cycles progressively denature the RCL and reduce inhibitory stoichiometry — even two additional cycles can produce a measurable increase in SI. On the day of use, thaw one aliquot on ice, spin briefly at 10,000 × g to pellet any microaggregates, and keep on ice throughout the experiment. Shelf life is 12 months from the date of receipt under proper storage. If you anticipate frequent use, prepare working aliquots of 5–10 µg in the supplied buffer and store those at -80°C, which provides greater stability than -20°C for long-term archiving.

Validation imagery coming soon

Western blot validation figures for REC-SerpinA3 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →